Healthcare stocks are soaring this year—Krystal Biotech, Exelixis, and CVS Health are leading the charge with explosive growth and major catalysts ahead. Krystal’s Vyjuvek, approved in Europe and Japan, treats rare skin conditions and has a robust pipeline. Exelixis is preparing to launch zanzalintinib for colorectal cancer to offset upcoming generic pressure on Cabometyx. CVS is turning around its insurance business and launching a new platform to boost weight-loss med sales. All three are primed for continued momentum with strong pipelines, expanding markets, and innovative patient solutions.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
